Where the Pain Used to Be
Editor's Note: Patient Worthy is honored to share this article from our friends at Elephants & Tea, originally written by Kiki Khan, a leukemia survivor. To see the article in…
Continue Reading
Where the Pain Used to Be
Jon’s Caregiver Story
Editor's Note: This post was written and submitted to us by Jon Scheinman, and originally shared on LinkedIn. To see the article in its original format, please click here. I…
Continue Reading
Jon’s Caregiver Story
Lilly’s Retatrutide Achieves Strong Weight Loss and Glycemic Benefits in Two Phase 3 Obesity Studies
As reported on Drugs, Eli Lilly has reported positive topline findings from two additional Phase 3 trials of retatrutide, its investigational triple hormone receptor agonist designed to target GIP, GLP-1,…
Continue Reading
Lilly’s Retatrutide Achieves Strong Weight Loss and Glycemic Benefits in Two Phase 3 Obesity Studies
AstraZeneca’s Triple-Inhaler Asthma Therapy Moves Closer to EU Approval
As reported on PharmaBiz, AstraZeneca has reached an important regulatory milestone in Europe after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Trixeo…
Continue Reading
AstraZeneca’s Triple-Inhaler Asthma Therapy Moves Closer to EU Approval
EMA Backs Enhertu Plus Pertuzumab as Potential New First-Line Standard for HER2-Positive Metastatic Breast Cancer
As reported on PharmaBiz, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation supporting approval of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate…
Continue Reading
EMA Backs Enhertu Plus Pertuzumab as Potential New First-Line Standard for HER2-Positive Metastatic Breast Cancer
Roche Ends Lupus T-Cell Engager Program but Maintains Focus on Autoimmune Cell Therapies
As reported on Fierce BioTech, Roche has discontinued development of its investigational T-cell engager (TCE) RG6382 for systemic lupus erythematosus (SLE), following an internal review that concluded the candidate lacked…
Continue Reading
Roche Ends Lupus T-Cell Engager Program but Maintains Focus on Autoimmune Cell Therapies
Novel HIV Vaccine Generates Strong Broadly Neutralizing Antibody Responses in Preclinical Study
Researchers from La Jolla Institute for Immunology (LJI), Scripps Research, and IAVI have reported a major advance in HIV vaccine development, demonstrating an experimental vaccine strategy that produced unusually strong…
Continue Reading
Novel HIV Vaccine Generates Strong Broadly Neutralizing Antibody Responses in Preclinical Study
An Eye-Opening Look into Coats’ Disease Research
Coats disease, is a rare retina condition diagnosed primarily in children. Symptoms may include, eye drift, blurry vision, the appearance of a white or silver looking retina, and retina detachment.…
Continue Reading
An Eye-Opening Look into Coats’ Disease Research
CHMP Backs Datroway for First-Line Treatment of Metastatic Triple-Negative Breast Cancer in EU
As reported on Stock Titan, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Datroway® (datopotamab deruxtecan) as a…
Continue Reading
CHMP Backs Datroway for First-Line Treatment of Metastatic Triple-Negative Breast Cancer in EU
FDA Review Raises Questions About Replimune’s Melanoma Therapy Ahead of Advisory Committee Vote
As reported on Reuters, Replimune’s experimental cancer treatment RP1 is facing increased regulatory scrutiny after U.S. Food and Drug Administration (FDA) reviewers expressed concerns about whether current clinical data adequately…
Continue Reading
FDA Review Raises Questions About Replimune’s Melanoma Therapy Ahead of Advisory Committee Vote
Cheryl’s Liver Cancer Story
In my younger years, beginning around the age of 30, I was living fast and careless. I was the party girl, always drinking, never thinking about what it might one…
Continue Reading
Cheryl’s Liver Cancer Story
FDA Clears Kenvue’s OTC Tylenol-Naproxen Combination for Long-Lasting Pain Relief
As reported on Pharmaceutical Technology, Kenvue has received US Food and Drug Administration (FDA) approval for an over-the-counter (OTC) pain medication that combines acetaminophen and naproxen sodium in a single…
Continue Reading
FDA Clears Kenvue’s OTC Tylenol-Naproxen Combination for Long-Lasting Pain Relief
CRISPR-Based RNA Editing May Boost Immunotherapy Response in Prostate Cancer
As reported on Science Daily, a novel CRISPR-driven RNA editing strategy could help overcome one of the biggest challenges in prostate cancer treatment: resistance to immunotherapy. Researchers have demonstrated that…
Continue Reading
CRISPR-Based RNA Editing May Boost Immunotherapy Response in Prostate Cancer
EU Approves Enhertu as First Tumor-Agnostic HER2-Targeted Antibody-Drug Conjugate
As reported on Stock Titan, the European Commission has approved Enhertu® (trastuzumab deruxtecan) as a treatment for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) solid tumors who…
Continue Reading
EU Approves Enhertu as First Tumor-Agnostic HER2-Targeted Antibody-Drug Conjugate
The Quiet Anger: Processing the Emotional Toll of Chronic Health Conditions
Living with chronic pain or other health conditions is, in many ways, an exercise in perpetual, involuntary mindfulness. For those of us navigating long-term conditions—like my own twenty‑five‑year journey with…
Continue Reading
The Quiet Anger: Processing the Emotional Toll of Chronic Health Conditions
FDA Clears TorEx Lung Perfusion System, Expanding Options for Donor Lung Assessment
As reported on TechTimes, the U.S. Food and Drug Administration (FDA) has granted Premarket Approval to the TorEx® Lung Perfusion System, a new ex vivo lung perfusion (EVLP) platform developed…
Continue Reading
FDA Clears TorEx Lung Perfusion System, Expanding Options for Donor Lung Assessment
FDA Issues Final Guidance for Psychedelic Drug Trials, Clarifying Expectations for Developers
As reported on Clinical Trials Arena, the US Food and Drug Administration (FDA) has released its final guidance on the clinical development of psychedelic therapies, providing drug developers with a…
Continue Reading
FDA Issues Final Guidance for Psychedelic Drug Trials, Clarifying Expectations for Developers
Alebund Initiates Global Phase IIb Trial of AP306 for Hyperphosphatemia in Hemodialysis Patients
As reported on PharmaBiz, Alebund Pharmaceuticals has announced the first patient has been enrolled and treated in a global Phase IIb clinical trial evaluating AP306, an investigational therapy for hyperphosphatemia…
Continue Reading
Alebund Initiates Global Phase IIb Trial of AP306 for Hyperphosphatemia in Hemodialysis Patients
Free Gene Therapy from Regeneron
As reported on Inside Precision Medicine, scientists have developed a way to spot a specific lung cancer mutation in just minutes instead of weeks, using a combination of advanced laser…
Continue Reading
Free Gene Therapy from Regeneron
Delcath Begins Phase 2 Study of HEPZATO in Liver-Dominant Metastatic Breast Cancer
As reported on Business Wire, Delcath Systems has announced the enrollment and dosing of the first patient in its global Phase 2 DELUMA clinical trial, marking a significant step in…
Continue Reading
Delcath Begins Phase 2 Study of HEPZATO in Liver-Dominant Metastatic Breast Cancer
Two of Intellia Therapeutics’ Clinical Trials That Had Been on Hold Have Now Been Released by the FDA
Two of Intellia Therapeutics’ clinical trials that had been on hold since October 2025 have now been released by the FDA. The Agency initially issued the holds due to reports…
Continue Reading
Two of Intellia Therapeutics’ Clinical Trials That Had Been on Hold Have Now Been Released by the FDA
Affinia Therapeutics Secures FDA Orphan Drug Designation for Investigational BAG3 Cardiomyopathy Gene Therapy
As reported on Pharmaceutical Business Review, Affinia Therapeutics has been granted orphan drug designation by the US Food and Drug Administration (FDA) for AFTX-201, an experimental gene therapy being developed…
Continue Reading
Affinia Therapeutics Secures FDA Orphan Drug Designation for Investigational BAG3 Cardiomyopathy Gene Therapy
FDA Authorization Positions Johnson & Johnson to Enter Competitive Surgical Robotics Market
As reported on Fierce BioTech, Johnson & Johnson has received U.S. Food and Drug Administration (FDA) clearance for its Ottava Robotic Surgical System, marking a significant step in the company’s…
Continue Reading
FDA Authorization Positions Johnson & Johnson to Enter Competitive Surgical Robotics Market
Scientists Find Poly-coated Nanoparticles Plus Therapeutic Drugs Have a Potential as Cancer Treatment
As reported on Science Daily, scientists have combined polymer-coated nanoparticles with therapeutic drugs for cancer treatment, including treatment for ovarian cancer. The nanoparticles target tumors and subsequently release their payloads,…
Continue Reading
Scientists Find Poly-coated Nanoparticles Plus Therapeutic Drugs Have a Potential as Cancer Treatment
Cincinnati Children’s Becomes Seventh U.S. Center Authorized to Deliver ZEVASKYN for RDEB Patients
As reported by The Manila Times, Abeona Therapeutics has announced that Cincinnati Children’s Hospital Medical Center has been designated as the seventh Qualified Treatment Center (QTC) authorized to administer ZEVASKYN®…
Continue Reading
Cincinnati Children’s Becomes Seventh U.S. Center Authorized to Deliver ZEVASKYN for RDEB Patients
